Drug research: myths, hype and reality
The DOI matches its Crossref record; 31 of the 32 references it cites were found in a registry or an index.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(96)00423-1 · Cited by 11,385
Molecular properties that influence the oral bioavailability of drug candidates
Veber, D. F., Johnson, S. R., Cheng, H.-Y., Smith, B. R., Ward, K. W., & Kopple, K. D. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm020017n · Cited by 8,420
Drug-like properties and the causes of poor solubility and poor permeability
Lipinski, C. A. (2000) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/s1056-8719(00)00107-6 · Cited by 3,734
Hopkins, A. L., & Groom, C. R. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd892 · Cited by 3,305
Ertl, P., Rohde, B., & Selzer, P. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm000942e · Cited by 3,084
ADMET in silico modelling: towards prediction paradise?
van de Waterbeemd, H., & Gifford, E. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1032 · Cited by 1,863
Molecular Complexity and Its Impact on the Probability of Finding Leads for Drug Discovery
Hann, M. M., Leach, A. R., & Harper, G. (2001) · Journal of Chemical Information and Computer Sciences · doi:10.1021/ci000403i · Cited by 877
The Design of Leadlike Combinatorial Libraries
Teague, S. J., Davis, A. M., Leeson, P. D., & Oprea, T. (1999) · Angewandte Chemie International Edition · doi:10.1002/(sici)1521-3773(19991216)38:24<3743::aid-anie3743>3.0.co;2-u · Cited by 870
Kelder, J., Grootenhuis, P. D. J., Bayada, D. M., Delbressine, L. P. C., & Ploemen, J.-P. (1999) · Pharmaceutical Research · doi:10.1023/a:1015040217741 · Cited by 813
Research works printed but not linked: 1
- Watson, J. D., with Berry, A. DNA. The Secret of Life. (William Heinemann, London, 2003).
Cited by
A BOILED‐Egg To Predict Gastrointestinal Absorption and Brain Penetration of Small Molecules
Daina, A., & Zoete, V. (2016) · ChemMedChem · doi:10.1002/cmdc.201600182 · Cited by 2,549
Multi-target therapeutics: when the whole is greater than the sum of the parts
Zimmermann, G. R., Lehár, J., & Keith, C. T. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2006.11.008 · Cited by 1,105
Vishwanathan, S. V. N., Schraudolph, N. N., Kondor, R., & Borgwardt, K. M. (2010) · CaltechAUTHORS (California Institute of Technology) · Cited by 1,305
Combining docking and molecular dynamic simulations in drug design
Alonso, H., Bliznyuk, A. A., & Gready, J. E. (2006) · Medicinal Research Reviews · doi:10.1002/med.20067 · Cited by 759
Halogen atoms in the modern medicinal chemistry: hints for the drug design
Hernandes, M., Cavalcanti, S. M., Moreira, D. R., de Azevedo Junior, W., & Leite, A. C. (2010) · Current Drug Targets · doi:10.2174/138945010790711996 · Cited by 723
Microengineered physiological biomimicry: Organs-on-Chips
Huh, D., Torisawa, Y.-S., Hamilton, G. A., Kim, H. J., & Ingber, D. E. (2012) · Lab on a Chip · doi:10.1039/c2lc40089h · Cited by 667
Computer-aided drug discovery and development (CADDD): in silico-chemico-biological approach
Kapetanovic, I. M. (2008) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2006.12.006 · Cited by 662
Millan, M. J. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.11.006 · Cited by 551
Pursuing the leadlikeness concept in pharmaceutical research
Hann, M. M., & Oprea, T. I. (2004) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2004.04.003 · Cited by 515
The application of in silico drug-likeness predictions in pharmaceutical research
Tian, S., Wang, J., Li, Y., Li, D., Xu, L., & Hou, T. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.01.009 · Cited by 498
Alavijeh, M. S., Chishty, M., Qaiser, M. Z., & Palmer, A. M. (2005) · NeuroRX · doi:10.1602/neurorx.2.4.554 · Cited by 497
A robustness-based approach to systems-oriented drug design
Kitano, H. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2195 · Cited by 488
In Situ Click Chemistry: Enzyme Inhibitors Made to Their Own Specifications
Manetsch, R., Krasiński, A., Radić, Z., Raushel, J., Taylor, P., Sharpless, K. B., & Kolb, H. C. (2004) · Journal of the American Chemical Society · doi:10.1021/ja046382g · Cited by 423
Drug discovery beyond the ‘rule-of-five’
Zhang, M.-Q., & Wilkinson, B. (2007) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2007.10.005 · Cited by 418
Unexplored therapeutic opportunities in the human genome
Oprea, T. I., Bologa, C. G., Brunak, S., Campbell, A., Gan, G. N., Gaulton, A., Gomez, S. M., Guha, R., Hersey, A., Holmes, J., et al. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.14 · Cited by 378
Regenmortel, M. H. V. V. (2004) · EMBO reports · doi:10.1038/sj.embor.7400284 · Cited by 357
Ou-Yang, S.-S., Lu, J.-Y., Kong, X.-Q., Liang, Z.-J., Luo, C., & Jiang, H. (2012) · Acta Pharmacologica Sinica · doi:10.1038/aps.2012.109 · Cited by 352
Binding MOAD (Mother Of All Databases)
Hu, L., Benson, M. L., Smith, R. D., Lerner, M. G., & Carlson, H. A. (2005) · Proteins: Structure, Function, and Bioinformatics · doi:10.1002/prot.20512 · Cited by 328
“Smaller molecules would tend to provide better oral absorption and fewer functional groups for toxicity concerns.[139, 122, 140, 141] Of course, ligand efficiencies reflect “bindability”, and it is important to recognize that there are additional properties that make a protein a suitable drug target.”
BackgroundTime-Related Differences in the Physical Property Profiles of Oral Drugs
Leeson, P. D., & Davis, A. M. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm049717d · Cited by 326
Erratum: Unexplored therapeutic opportunities in the human genome
Oprea, T. I., Bologa, C. G., Brunak, S., Campbell, A., Gan, G. N., Gaulton, A., Gomez, S. M., Guha, R., Hersey, A., Holmes, J., et al. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.52 · Cited by 311
Cooper, T. W. J., Campbell, I. B., & Macdonald, S. J. F. (2010) · Angewandte Chemie International Edition · doi:10.1002/anie.201002238 · Cited by 299
A practical view of ‘druggability’
Keller, T. H., Pichota, A., & Yin, Z. (2006) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2006.06.014 · Cited by 295
Koutsoukas, A., Simms, B., Kirchmair, J., Bond, P. J., Whitmore, A. V., Zimmer, S., Young, M. P., Jenkins, J. L., Glick, M., Glen, R. C., et al. (2011) · Journal of Proteomics · doi:10.1016/j.jprot.2011.05.011 · Cited by 287
Assessing drug-likeness – what are we missing?
Vistoli, G., Pedretti, A., & Testa, B. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2007.11.007 · Cited by 278
Ursu, O., Rayan, A., Goldblum, A., & Oprea, T. I. (2011) · WIREs Computational Molecular Science · doi:10.1002/wcms.52 · Cited by 276
Can cell systems biology rescue drug discovery?
Butcher, E. C. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1754 · Cited by 276
FAF-Drugs2: Free ADME/tox filtering tool to assist drug discovery and chemical biology projects
Lagorce, D., Sperandio, O., Galons, H., Miteva, M. A., & Villoutreix, B. O. (2008) · BMC Bioinformatics · doi:10.1186/1471-2105-9-396 · Cited by 263
Large-scale investigation of the reasons why potentially important genes are ignored
Stoeger, T., Gerlach, M., Morimoto, R. I., & Nunes Amaral, L. A. (2018) · PLOS Biology · doi:10.1371/journal.pbio.2006643 · Cited by 261
The myth of the biotech revolution
Nightingale, P., & Martin, P. (2004) · Trends in Biotechnology · doi:10.1016/j.tibtech.2004.09.010 · Cited by 259
Reactions and enzymes in the metabolism of drugs and other xenobiotics
Testa, B., Pedretti, A., & Vistoli, G. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.01.017 · Cited by 254
The graphical representation of ADME-related molecule properties for medicinal chemists
Ritchie, T. J., Ertl, P., & Lewis, R. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2010.11.002 · Cited by 249
Adversarial Threshold Neural Computer for Molecular de Novo Design
Putin, E., Asadulaev, A., Vanhaelen, Q., Ivanenkov, Y., Aladinskaya, A. V., Aliper, A., & Zhavoronkov, A. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.7b01137 · Cited by 211
Early prediction of drug metabolism and toxicity: systems biology approach and modeling
Bugrim, A., Nikolskaya, T., & Nikolsky, Y. (2004) · Drug Discovery Today · doi:10.1016/s1359-6446(03)02971-4 · Cited by 188
Navigating structure–activity landscapes
Bajorath, J., Peltason, L., Wawer, M., Guha, R., Lajiness, M. S., & Van Drie, J. H. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2009.04.003 · Cited by 172
Integrated gut/liver microphysiological systems elucidates inflammatory inter‐tissue crosstalk
Chen, W. L. K., Edington, C., Suter, E., Yu, J., Velazquez, J. J., Velazquez, J. G., Shockley, M., Large, E. M., Venkataramanan, R., Hughes, D. J., et al. (2017) · Biotechnology and Bioengineering · doi:10.1002/bit.26370 · Cited by 172
Structure-Based Drug Design Strategies in Medicinal Chemistry
Andricopulo, A., Salum, L., & Abraham, D. (2009) · Current Topics in Medicinal Chemistry · doi:10.2174/156802609789207127 · Cited by 161
Swales, J. G., Hamm, G. R., Clench, M. R., & Goodwin, R. J. A. (2018) · International Journal of Mass Spectrometry · doi:10.1016/j.ijms.2018.02.007 · Cited by 159
Koutsoukas, A., Lowe, R., KalantarMotamedi, Y., Mussa, H. Y., Klaffke, W., Mitchell, J. B. O., Glen, R. C., & Bender, A. (2013) · Journal of Chemical Information and Modeling · doi:10.1021/ci300435j · Cited by 147
Optimal assignment kernels for attributed molecular graphs
Fröhlich, H., Wegner, J. K., Sieker, F., & Zell, A. (2005) · International Conference on Machine Learning · doi:10.1145/1102351.1102380 · Cited by 145
Katritch, V., Rueda, M., Lam, P. C., Yeager, M. J., & Abagyan, R. A. (2009) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.22507 · Cited by 141
Concepts and applications of chemical fingerprint for hit and lead screening
Yang, J., Cai, Y., Zhao, K., Xie, H., & Chen, X. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.103356 · Cited by 167
Yang, Y., Engkvist, O., Llinàs, A., & Chen, H. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm201548z · Cited by 149
FAF-Drugs: free ADME/tox filtering of compound collections
Miteva, M. A., Violas, S., Montès, M., Gomez, D. A., Tufféry, P., & Villoutreix, B. O. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkl065 · Cited by 143
Tsaioun, K. (2016) · ALTEX · doi:10.14573/altex.1610101 · Cited by 131
The Multiscale Laplacian Graph KernelPreprint
Kondor, R., & Pan, H. (2016) · arXiv (Cornell University) · doi:10.48550/arxiv.1603.06186 · Cited by 139
Palmer, D. S., & Mitchell, J. B. O. (2014) · Molecular Pharmaceutics · doi:10.1021/mp500103r · Cited by 131
Tautomerism in Computer‐Aided Drug Design
Pospisil, P., Ballmer, P., Scapozza, L., & Folkers, G. (2003) · Journal of Receptors and Signal Transduction · doi:10.1081/rrs-120026975 · Cited by 121
Gleeson, M. P., Bravi, G., Modi, S. P., & Lowe, D. M. (2009) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2009.07.002 · Cited by 111
Prediction methods and databases within chemoinformatics: emphasis on drugs and drug candidates
Jónsdóttir, S. Ó., Jørgensen, F. S., & Brunak, S. (2005) · Computer applications in the biosciences · doi:10.1093/bioinformatics/bti314 · Cited by 124
Near-optimal supervised feature selection among frequent subgraphs
Thoma, M., Cheng, H., Gretton, A., Han, J., Kriegel, H., Smola, A. J., Song, L., Yu, P. S., Yan, X., & Borgwardt, K. M. (2009) · SIAM International Conference on Data Mining · doi:10.1137/1.9781611972795.92 · Cited by 104
Automation and data-driven design of polymer therapeutics
Upadhya, R., Kosuri, S., Tamasi, M., Meyer, T. A., Atta, S., Webb, M. A., & Gormley, A. J. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.11.009 · Cited by 113
Fragonomics: fragment-based drug discovery
Zartler, E. R., & Shapiro, M. J. (2005) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2005.05.002 · Cited by 104
ADDME – Avoiding Drug Development Mistakes Early: central nervous system drug discovery perspective
Tsaioun, K., Bottlaender, M., Mabondzo, A., & the Alzheimer's Drug Discovery Foundation (2009) · BMC Neurology · doi:10.1186/1471-2377-9-s1-s1 · Cited by 103
First-Principles Calculation of the Intrinsic Aqueous Solubility of Crystalline Druglike Molecules
Palmer, D. S., McDonagh, J. L., Mitchell, J. B. O., van Mourik, T., & Fedorov, M. V. (2012) · Journal of Chemical Theory and Computation · doi:10.1021/ct300345m · Cited by 103
Challenges in the Search for Drugs to Treat Central Nervous System Disorders
Enna, S. J., & Williams, M. C. (2009) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.143420 · Cited by 107
Grafting of 3D Bioprinting to In Vitro Drug Screening: A Review
Nie, J., Gao, Q., Fu, J., & He, Y. (2020) · Advanced Healthcare Materials · doi:10.1002/adhm.201901773 · Cited by 106
The future of drug discovery and development: Shifting emphasis towards personalized medicine
Amir-Aslani, A., & Mangematin, V. (2009) · Technological Forecasting and Social Change · doi:10.1016/j.techfore.2009.09.005 · Cited by 115
New frontiers in proteomics research: A perspective
Dhingra, V., Gupta, M., Andacht, T. M., & Fu, Z. F. (2005) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2005.04.010 · Cited by 119
High‐order combination effects and biological robustness
Lehár, J., Krueger, A., Zimmermann, G., & Borisy, A. (2008) · Molecular Systems Biology · doi:10.1038/msb.2008.51 · Cited by 95
Rather, M. A., Bhat, B. A., & Qurishi, M. A. (2013) · Phytomedicine · doi:10.1016/j.phymed.2013.07.015 · Cited by 101
Use of Radioactive Compounds and Autoradiography to Determine Drug Tissue Distribution
Solon, E. G. (2012) · Chemical Research in Toxicology · doi:10.1021/tx200509f · Cited by 94
Comparison of protein active site structures for functional annotation of proteins and drug design
Powers, R., Copeland, J. C., Germer, K., Mercier, K., Ramanathan, V., & Revesz, P. Z. (2006) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.21092 · Cited by 102
Probabilistic Approaches in Activity Prediction
Filimonov, D. A., & Poroikov, V. (2008) · Royal Society of Chemistry eBooks · doi:10.1039/9781847558879-00182 · Cited by 135
Impact of ion class and time on oral drug molecular properties
Leeson, P. D., St-Gallay, S. A., & Wenlock, M. C. (2010) · MedChemComm · doi:10.1039/c0md00157k · Cited by 87
Fragment-based QSAR: perspectives in drug design
Salum, L. B., & Andricopulo, A. D. (2009) · Molecular Diversity · doi:10.1007/s11030-009-9112-5 · Cited by 94
Computer-Aided Drug Discovery and Development
Zhang, S. (2011) · Methods in Molecular Biology · doi:10.1007/978-1-61779-012-6_2 · Cited by 78
Fragment Based Drug Discovery: Practical Implementation Based on 19F NMR Spectroscopy
Jordan, J. B., Poppe, L., Xia, X., Cheng, A. C., Sun, Y., Michelsen, K., Eastwood, H. A., Schnier, P. D., Nixey, T. E., & Zhong, W. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm201441k · Cited by 86
Assessing How Well a Modeling Protocol Captures a Structure−Activity Landscape
Guha, R., & Drie, J. H. V. (2008) · Journal of Chemical Information and Modeling · doi:10.1021/ci8001414 · Cited by 85
NGP1-01, a lipophilic polycyclic cage amine, is neuroprotective in focal ischemia
Mdzinarishvili, A., Geldenhuys, W. J., Abbruscato, T. J., Bickel, U., Klein, J., & der Schyf, C. J. V. (2005) · Neuroscience Letters · doi:10.1016/j.neulet.2005.03.042 · Cited by 80
Protein NMR in biomedical research
Jahnke, W., & Widmer, H. M. (2004) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-003-3382-3 · Cited by 84
Grime, K. H., Barton, P., & McGinnity, D. F. (2013) · Molecular Pharmaceutics · doi:10.1021/mp300476z · Cited by 78
Quantitation of Endogenous Metabolites in Mouse Tumors Using Mass-Spectrometry Imaging
Swales, J. G., Dexter, A., Hamm, G. R., Nilsson, A., Strittmatter, N., Michopoulos, F., Hardy, C., Gutierrez, P. M., Mellor, M. J., Andrén, P. E., et al. (2018) · Analytical Chemistry · doi:10.1021/acs.analchem.7b05239 · Cited by 77
Khan, T., Ahmad, R., Azad, I., Raza, S., Joshi, S., & Khan, A. R. (2018) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2018.05.008 · Cited by 77
3S - Systematic, systemic, and systems biology and toxicology
Smirnova, L. (2018) · ALTEX · doi:10.14573/altex.1804051 · Cited by 72
McDiarmid, T. A., Belmadani, M., Liang, J., Meili, F., Mathews, E., Mullen, G. P., Hendi, A., Wong, W.-R., Rand, J. B., Mizumoto, K., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1912049116 · Cited by 78
Graph KernelsPreprint
Vishwanathan, S. V. N., Borgwardt, K. M., Kondor, I. R., & Schraudolph, N. N. (2008) · arXiv (Cornell University) · Cited by 76
Artificial Intelligence in Drug Design: Algorithms, Applications, Challenges and Ethics
Arabi, A. A. (2021) · Future Drug Discovery · doi:10.4155/fdd-2020-0028 · Cited by 85
Segall, M., Beresford, A. P., Gola, J. M. R., Hawksley, D., & Tarbit, M. (2006) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2.2.325 · Cited by 71
Azad, I., Nasibullah, M., Khan, T., Hassan, F., & Akhter, Y. (2018) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2018.02.013 · Cited by 72
Are natural products still the best source for antibacterial discovery? The bacterial entry factor
Silver, L. L. (2008) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.3.5.487 · Cited by 78
(2004) · PubMed · Cited by 66
CDA: Combinatorial Drug Discovery Using Transcriptional Response Modules
Lee, J. H., Kim, D. G., Bae, T., Rho, K., Kim, J. T., Lee, J.-J., Jang, Y., Kim, B. C., Park, K. M., & Kim, S. (2012) · PLoS ONE · doi:10.1371/journal.pone.0042573 · Cited by 73
Computational modeling of human oral bioavailability: what will be next?
Cabrera‐Pérez, M. Á., & Pham‐The, H. (2018) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2018.1463988 · Cited by 70
The screening toolbox of bioactive substances from natural products: A review
Wang, B., Deng, J., Gao, Y., Zhu, L., He, R., & Xu, Y. (2011) · Fitoterapia · doi:10.1016/j.fitote.2011.08.007 · Cited by 69
Lipid‐Bilayer Permeation of Drug‐Like Compounds
Krämer, S. D., Lombardi, D., Primorac, A., Thomae, A. V., & Wunderli‐Allenspach, H. (2009) · Chemistry & Biodiversity · doi:10.1002/cbdv.200900122 · Cited by 63
Hussain, W., Rasool, N., & Khan, Y. D. (2020) · Current Drug Discovery Technologies · doi:10.2174/1570163817666200806165934 · Cited by 64
Docking and Ligand Binding Affinity: Uses and Pitfalls
Yunta, M. J. R. (2016) · American Journal of Modeling and Optimization · doi:10.12691/ajmo-4-3-2 · Cited by 89
Cheminformatics analysis of natural products: Lessons from nature inspiring the design of new drugs
Ertl, P., & Schuffenhauer, A. (2008) · Birkhäuser Basel eBooks · doi:10.1007/978-3-7643-8595-8_4 · Cited by 62
Productivity Shortfalls in Drug Discovery: Contributions from the Preclinical Sciences?
Williams, M. J. (2010) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.171751 · Cited by 65
Heterogeneity and emergent behaviour in the vascular endothelium
McCarron, J. G., Wilson, C., Heathcote, H. R., Zhang, X., Buckley, C., & Lee, M. D. (2019) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2019.03.008 · Cited by 61
Wang, L., Cai, X., Shi, M., Xue, L., Kuang, S., Xu, R., Qi, W., Li, Y., Ma, X., Zhang, R., et al. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112385 · Cited by 58
Komatsu, T., & Urano, Y. (2015) · Analytical Sciences · doi:10.2116/analsci.31.257 · Cited by 57
Mass Spectrometry Imaging in Oncology Drug Discovery
Goodwin, R. J. A., Bunch, J., & McGinnity, D. F. (2017) · Advances in cancer research · doi:10.1016/bs.acr.2016.11.005 · Cited by 67
Khan, T., Lawrence, A. J., Azad, I., Raza, S., Joshi, S., & Khan, A. R. (2019) · Current Computer - Aided Drug Design · doi:10.2174/1573399815666190326120006 · Cited by 57
Austin, C. P. (2004) · Annual Review of Medicine · doi:10.1146/annurev.med.55.091902.104426 · Cited by 57
The Current State of Drug Discovery and a Potential Role for NMR Metabolomics
Powers, R. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401803b · Cited by 62
Cooper, T. W. J., Campbell, I. B., & Macdonald, S. J. F. (2010) · Angewandte Chemie · doi:10.1002/ange.201002238 · Cited by 52
The rational design of biological complexity: A deceptive metaphor
Regenmortel, M. H. V. V. (2007) · PROTEOMICS · doi:10.1002/pmic.200600407 · Cited by 52
Evolution of Experimental Models of the Liver to Predict Human Drug Hepatotoxicity and Efficacy
Vernetti, L. A., Vogt, A., Gough, A., & Taylor, D. L. (2016) · Clinics in Liver Disease · doi:10.1016/j.cld.2016.08.013 · Cited by 57
Ligand specificity, privileged substructures and protein druggability from fragment-based screening
Barelier, S., & Krimm, I. (2011) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2011.02.020 · Cited by 51
Metadata
- Authors
- Kubinyi, H.
- Corresponding author
- Kubinyi, Hugo
- Venue
- Nature Reviews Drug Discovery
- Published
- 2003-08
- Volume
- 2
- Issue
- 8
- Pages
- 665-668
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W1487233798
- Cited by
- 348
- References
- 32
- Citations by year
- 2026: 3 · 2025: 3 · 2024: 13 · 2023: 6 · 2022: 9 · 2021: 4 · 2020: 9 · 2019: 16 · 2018: 24 · 2017: 8 · 2016: 15 · 2015: 17 · 2014: 16 · 2013: 17 · 2012: 26
- FWCI
- 1.69
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Physical Sciences › Chemistry › Organic Chemistry › Synthesis and Characterization of Heterocyclic Compounds
- Keywords
- drug discovery, lead-like compounds, drug-like molecules, oral bioavailability, combinatorial chemistry, high-throughput screening, ADME, computer-aided drug design, structure-based drug design, lead optimization, medicinal chemistry
- MeSH terms
- Chemistry, Pharmaceutical, Humans, Pharmacokinetics, Pharmacology, Research, Technology, Pharmaceutical
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.